Premaitha Health PLC Grant of Options (1077N)
October 21 2016 - 2:00AM
UK Regulatory
TIDMNIPT
RNS Number : 1077N
Premaitha Health PLC
21 October 2016
Premaitha Health plc
("Premaitha" or the "Company")
Grant of Options
Manchester, UK - 21 October 2016: Premaitha Health plc (AIM:
NIPT), developer of the leading CE-marked complete non-invasive
prenatal screening system, makes the following announcement:
Grant of share options
The Company has today issued 940,000 options over ordinary
shares under the Company's unapproved share option scheme to two
employees. The options are exercisable at any time up to 20 October
2026, subject to performance conditions, at a price of 20 pence per
share. Following the issue of these options, the Company has
36,785,030 shares under option and a further 40,272,076 shares
under warrant.
The issued share capital of the Company comprises 228,163,709
Ordinary Shares of 10p each.
For more information, please contact:
Premaitha Health plc Tel: +44 (0)
161 667 6865
Dr Stephen Little, Chief Executive
Office
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)
20 7213 0880
Liam Murray / James Caithie
finnCap (Broker) Tel: +44 (0)
20 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
20 7830 9704
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
About Premaitha
Premaitha is a molecular diagnostics company which uses the
latest advances in DNA analysis technology to develop safer, faster
and regulatory approved non-invasive screening tests for pregnant
women.
Premaitha's lead test - the IONA(R) test - was launched in
February 2015 and is the leading CE-marked complete system which
estimates the risk of a fetus being affected with Down's syndrome
or other genetic conditions. The IONA(R) test is performed on the
mother's blood sample - which contains traces of fetal DNA - and
then analysed using next generation DNA sequencing technology from
ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary stressful and invasive
follow up diagnostic procedures which are costly, resource
intensive and carry a risk of miscarriage.
Non-invasive prenatal screening is an emerging, multi-billion
dollar global market and Premaitha's CE-marked complete system
enables laboratories and healthcare practitioners to offer an
approved, non-invasive prenatal screening solution in-house.
Premaitha is based in Manchester Science Park, United Kingdom
and its shares trade on the AIM market of the London Stock Exchange
(AIM: NIPT). For further information please visit
www.premaitha.com. Follow us on twitter @PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLBDGBGDBGLG
(END) Dow Jones Newswires
October 21, 2016 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024